Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
- PMID: 38568026
- DOI: 10.1002/ana.26913
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
Abstract
Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a smoldering inflammatory activity is present from the earliest stages of the disease and underlies the progression of disability, which proceeds relentlessly and independently of clinical and radiological relapses (PIRA). The complex system of pathological events driving "chronic" worsening is likely linked with the early accumulation of compartmentalized inflammation within the central nervous system as well as insufficient repair phenomena and mitochondrial failure. These mechanisms are partially lesion-independent and differ from those causing clinical relapses and the formation of new focal demyelinating lesions; they lead to neuroaxonal dysfunction and death, myelin loss, glia alterations, and finally, a neuronal network dysfunction outweighing central nervous system (CNS) compensatory mechanisms. This review aims to provide an overview of the state of the art of neuropathological, immunological, and imaging knowledge about the mechanisms underlying the smoldering disease activity, focusing on possible early biomarkers and their translation into clinical practice. ANN NEUROL 2024;96:1-20.
© 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Similar articles
-
A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective.Int J Mol Sci. 2025 Jan 21;26(3):884. doi: 10.3390/ijms26030884. Int J Mol Sci. 2025. PMID: 39940654 Free PMC article. Review.
-
[Prognostic significance of smoldering disease in multiple sclerosis, monitoring progression by imaging].Ideggyogy Sz. 2025 Mar 30;78(3-04):79-85. doi: 10.18071/isz.77.0079. Ideggyogy Sz. 2025. PMID: 40163009 Review. Hungarian.
-
The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?J Neuroinflammation. 2024 Aug 21;21(1):209. doi: 10.1186/s12974-024-03193-6. J Neuroinflammation. 2024. PMID: 39169320 Free PMC article. Review.
-
How patients with multiple sclerosis acquire disability.Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016. Brain. 2022. PMID: 35104840 Free PMC article.
-
Biomarkers of Progression Independent of Relapse Activity-Can We Actually Measure It Yet?Int J Mol Sci. 2025 May 14;26(10):4704. doi: 10.3390/ijms26104704. Int J Mol Sci. 2025. PMID: 40429847 Free PMC article. Review.
Cited by
-
T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis.Cell Rep Med. 2025 Mar 18;6(3):102027. doi: 10.1016/j.xcrm.2025.102027. Cell Rep Med. 2025. PMID: 40107244 Free PMC article.
-
Multiple sclerosis: 2024 update.Free Neuropathol. 2025 Jul 8;6:14. doi: 10.17879/freeneuropathology-2025-6762. eCollection 2025. Free Neuropathol. 2025. PMID: 40636815 Free PMC article. Review.
-
Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.Ann Clin Transl Neurol. 2025 Mar;12(3):615-630. doi: 10.1002/acn3.52311. Epub 2025 Feb 17. Ann Clin Transl Neurol. 2025. PMID: 39957675 Free PMC article.
-
Disability independent of cerebral white matter demyelination in progressive multiple sclerosis.Acta Neuropathol. 2024 Aug 31;148(1):34. doi: 10.1007/s00401-024-02796-w. Acta Neuropathol. 2024. PMID: 39217272 Free PMC article.
-
Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Italy.Neurol Ther. 2025 Aug;14(4):1507-1520. doi: 10.1007/s40120-025-00761-7. Epub 2025 Jun 4. Neurol Ther. 2025. PMID: 40461934 Free PMC article.
References
-
- Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014;83:278–286.
-
- Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse‐independent progression vs relapse‐associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020;77:1132–1140.
-
- Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain 2022;145:3147–3161.
-
- Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the “real MS”. Ther Adv Neurol Disord 2022;15:17562864211066752.
-
- Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real‐life cohort study. Brain 2022;145:2796–2805.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical